Eculizumab

Introduction Overview

Generic Name

eculizumab

Brand Name

Soliris

Dosage Form

injection for intravenous infusion

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Eculizumab (Soliris) is administered intravenously, ensuring complete bioavailability by direct entry into systemic circulation. The absorption phase observed with orally administered drugs is bypassed, providing prompt therapeutic levels within a short duration of infusion (typically 35 minutes in adults). This intravenous route eliminates concerns of gastrointestinal variability often seen with oral drugs.

Distribution:
Once administered, eculizumab distributes primarily within the vascular and interstitial compartments. Being a large monoclonal antibody (approximately 148 kDa), its tissue penetration beyond vascular spaces is limited but sufficient for targeting complement protein C5 circulating in plasma. Eculizumab does not notably cross the blood-brain barrier under normal conditions. Its volume of distribution remains low, approximating plasma volume, consistent with its molecular size and pharmacological target location.

Metabolism:
Eculizumab, like other monoclonal antibodies, is metabolized through catabolic pathways; primarily via proteolytic degradation to small peptides and amino acids by reticuloendothelial system cells and endothelial cells. It is not metabolized by cytochrome P450 enzymes, minimizing classical drug-drug metabolism interactions. The metabolism is slow and occurs through natural immunoglobulin clearance mechanisms.

Elimination:
The elimination half-life of eculizumab is approximately 11 days, allowing for biweekly dosing regimens after initial loading doses. Clearance occurs mainly via reticuloendothelial system through nonspecific catabolism, rather than renal or hepatic routes. There is no significant renal excretion of active drug due to its size. Clearance may be affected by high circulating levels of its target antigen C5, as immune complexes are cleared. Steady-state levels are reached after 4 weeks of weekly dosing. Clinical implications include the need for consistent dosing to maintain complement inhibition and prevent breakthrough hemolysis or relapse in treated conditions.

Dosage Forms

Available Dosage Forms:
Soliris is supplied as a single-dose vial for intravenous infusion:
- Injection single-dose vial: 300 mg/30 mL (10 mg/mL) concentration.

Dosages for Adults and Adolescents:
- Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults: 600 mg IV weekly for 4 weeks, then 900 mg at week 5, followed by 900 mg every 2 weeks.
- Atypical Hemolytic Uremic Syndrome (aHUS) in adults: 900 mg IV weekly for first 4 weeks, then 1200 mg at week 5, followed by 1200 mg every 2 weeks.
- Generalized Myasthenia Gravis (gMG) in adults: same dosing as aHUS.
- Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults: same dosing as aHUS and gMG.

Specific Patient Populations:
- Children and adolescents with aHUS and gMG (6 years and older) receive weight-based dosing:
- 5 to <10 kg: 300 mg at Week 1, followed by 300 mg at Week 2, then every 3 weeks.
- 10 to <20 kg: 600 mg Week 1, 300 mg Week 2, then every 2 weeks.
- 20 to <30 kg: 600 mg weekly for 2 weeks, followed by 600 mg at Week 3, then every 2 weeks.
- 30 to <40 kg: 600 mg weekly for 2 weeks, then 900 mg at Week 3, then every 2 weeks.
- ≥40 kg: adult dosing regimen.

Clinical Guidelines:
The infusion is administered intravenously over 35 minutes (adults) or 1-4 hours (children) under healthcare professional supervision with monitoring for infusion reactions at least 1 hour post-infusion. Dose adjustments or infusion rate modifications may be necessary in event of infusion-related reactions. Missing doses should prompt immediate medical consultation to avoid disease relapse or breakthrough symptoms.

Mechanism Of Action

Eculizumab (Soliris) is a recombinant humanized monoclonal IgG2/4k antibody that selectively binds to the complement protein C5, inhibiting its cleavage into C5a and C5b, critical components in the terminal complement cascade. By binding C5 with high affinity, Soliris prevents the generation of the membrane attack complex (MAC), C5b-9, which is responsible for cell lysis.

The complement system is an essential part of innate immunity, composed of a cascade of proteins that facilitate pathogen clearance and immune responses. In pathologic conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and others, aberrant activation of the terminal complement pathway causes host cell damage, especially red blood cells.

By blocking the terminal complement pathway, Soliris inhibits intravascular hemolysis in PNH, preventing the destruction of red blood cells and resulting in reduced anemia, fatigue, and thrombotic events. In aHUS, complement-mediated endothelial damage and microangiopathy are reduced, mitigating renal injury and thrombosis.

In generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), Soliris modulates pathogenic complement-mediated damage to neuromuscular junctions and central nervous system structures, respectively. This immunomodulatory effect preserves normal function by preventing complement-mediated inflammation and tissue injury.

Comparatively, Soliris's mechanism is distinct from other immunosuppressants that broadly inhibit immune function; its targeted approach offers effective disease control with a focused action on complement C5, supported by clinical studies demonstrating marked efficacy and improved patient outcomes across approved indications.

Pharmacological Actions

Selective inhibition of complement protein C5 to block terminal complement activation.
Prevention of formation of the membrane attack complex (C5b-9), blocking cell lysis.
Reduction of intravascular hemolysis in paroxysmal nocturnal hemoglobinuria.
Prevention of complement-mediated microangiopathy in atypical hemolytic uremic syndrome.
Modulation of immune-mediated neuromuscular junction damage in myasthenia gravis.
Reduction of complement-driven central nervous system inflammation in NMOSD.
Monoclonal antibody-mediated immunosuppression with minimal off-target effects.
Prolongation of red blood cell survival and reduction of anemia-related symptoms.
Mitigation of thrombotic risks associated with complement activation.
Immunomodulatory effects preserving tissue integrity through complement inhibition.
No direct cytotoxicity; therapeutic effect derived from complement pathway blockade.
Biological agent with prolonged half-life allowing biweekly dosing schedules.
Potential to decrease frequency of disease exacerbations or relapses.
Improvement in quality of life in patients with complement-mediated disorders.

Therapeutic Or Clinical Uses

Treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults to reduce hemolysis and thrombosis.
Management of atypical hemolytic uremic syndrome (aHUS) in adults and pediatric patients to prevent thrombotic microangiopathy.
Use in generalized myasthenia gravis (gMG) for adults and children 6 years and older who are anti-acetylcholine receptor antibody positive, to improve muscular strength.
Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive to reduce relapses.
Off-label use considerations in other complement-mediated disorders under investigational protocols.
Prevention of long-term complications related to complement-mediated endothelial and red blood cell damage.
Use as part of a comprehensive therapeutic strategy including vaccination and infection monitoring.
Reduction in need for blood transfusions in PNH patients by controlling hemolysis.
Improvement of renal function markers in aHUS through complement blockade.
Adjunctive therapy to reduce disease progression in autoimmune neuromuscular diseases.
Expansion of indications through ongoing clinical studies on complement-mediated pathologies.
Alternative to plasma exchange and immunosuppressive therapies in select cases.
Treatment in patients with refractory or recurrent complement-driven conditions.
Useful in preventing thrombotic complications by interrupting complement activation pathway.
Facilitates improved patient outcomes by targeting a pathophysiologic mechanism.

Side Or Adverse Effects

Headache and dizziness are common neurological complaints post-infusion.
Flu-like symptoms including fever, fatigue, myalgias, and cough.
Upper respiratory tract symptoms: runny or stuffy nose and sinus pain.
Urinary tract infections and painful urination reported in some patients.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and abdominal pain.
Peripheral edema presenting as swelling in legs or feet.
Bruising and potential blood cell disorders such as anemia or thrombocytopenia.
Musculoskeletal pain including muscle aches, joint pain, and back pain.
Elevated blood pressure and hypertension incidents.
Serious infusion-related reactions: chest pain, swelling of face or throat, difficulty breathing, syncope.
Increased risk of serious meningococcal infections due to complement blockade.
Susceptibility to other encapsulated bacterial infections (e.g., Streptococcus pneumoniae).
Potential fungal infections like aspergillosis in immunocompromised patients.
Hypersensitivity and allergic reactions potentially occurring during infusion.
Rare reports of blood clots and thrombotic events despite treatment.

Precautions

Patients must receive meningococcal vaccination at least 2 weeks prior to starting Soliris.
Continuous monitoring for signs and symptoms of meningococcal and other serious infections during and after treatment.
Healthcare providers should educate patients on early symptom recognition of meningococcal infection.
Careful assessment before initiating in patients with active infection or fever.
Consideration of vaccination against Streptococcus pneumoniae and Haemophilus influenzae in pediatric patients.
Close monitoring of blood pressure, renal function, and neurological status during therapy.
Infusion should be administered under supervision with an emergency response plan for severe reactions.
Do not discontinue therapy abruptly without consulting a healthcare provider to avoid hemolytic or thrombotic complications.
In patients with neuromyelitis optica, evaluate antibody status to confirm treatment suitability.
Pregnancy and breastfeeding require risk-benefit assessment; insufficient data on fetal safety.
Monitor for infusion-related reactions and adjust infusion rate accordingly.
Monitor complete blood counts to detect possible cytopenias or hemolysis.
Educate patients to carry a Patient Safety Card regarding infection risk for at least 3 months post-treatment.
Assess for gonorrhea risk and provide preventive counseling and testing if indicated.
Use caution in immunosuppressed patients due to increased infection susceptibility.

Warnings

Boxed Warning for life-threatening meningococcal infections associated with complement inhibition.
Serious and potentially fatal infections can develop rapidly; immediate medical attention is critical.
Infusion-related reactions can be severe, including anaphylaxis, warranting emergency preparedness.
Risk of breakthrough hemolysis or thrombotic events if treatment is interrupted or discontinued.
Vaccination does not eliminate the risk of meningococcal infection; vigilant clinical monitoring is essential.
Increased susceptibility to serious infections with encapsulated bacteria including Neisseria gonorrhoeae.
Potential for serious kidney complications and thrombotic microangiopathy upon treatment cessation in aHUS.
Avoid use in patients with Shiga toxin-producing E. coli-related HUS as Soliris is ineffective.
High risk of severe infections in patients with compromised immune systems or low white blood cell counts.
May cause serious allergic reactions during infusion with symptoms like facial swelling and respiratory distress.
Use caution during pregnancy; disease control must be balanced against potential fetal risks.
Risk of hypertension and neurological symptoms requiring prompt evaluation.
Patients must be instructed to seek emergency care with symptoms suggesting meningitis or sepsis.
Treatment requires enrollment in the Ultomiris and Soliris REMS program to ensure safety measures.
Post-treatment risk period for infections extends weeks after last dose; continued vigilance required.

Contraindication

Patients with unresolved or active meningococcal infection should not receive Soliris.
Individuals not vaccinated against meningococcus are contraindicated unless vaccination is completed.
Known hypersensitivity to eculizumab or any excipients present in the formulation.
Patients with Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome (STEC-HUS).
Do not use during episodes of uncontrolled infection including bacterial, viral, or fungal diseases.
Contraindicated in patients with history of severe infusion-related hypersensitivity reactions to Soliris.
Pregnant or breastfeeding individuals unless benefits outweigh potential risks and under strict supervision.
Severe uncontrolled hypertension or unstable cardiovascular conditions requiring stabilization first.
Patients who are non-compliant or unable to adhere to monitoring and vaccination requirements.
Individuals with active systemic autoimmune diseases other than indications for Soliris use.
Contraindicated in patients with severely impaired immune response or severe neutropenia.
Use is inadvisable in patients with acute renal failure from causes other than aHUS without specialist input.
Contraindications extend to patients lacking access to emergency medical care for infusion complications.
Patients with known hypersensitivity to murine or chimeric monoclonal antibodies (prior severe reactions).
Avoid in patients with documented allergy to any component of Soliris, including polysorbate 80.

Drug Interactions

No significant cytochrome P450-mediated drug interactions expected due to monoclonal antibody nature.
Concomitant administration with live vaccines is not recommended; timing with vaccination crucial.
Potential increased risk of infections when combined with other immunosuppressive agents or therapies.
Drugs that depress immune function (e.g., corticosteroids, chemotherapeutics) require careful monitoring when coadministered.
Eculizumab may alter response to vaccines due to complement blockade, potentially reducing vaccine efficacy.
Medication adherence critical; interruptions may result in disease exacerbation or adverse events.
No known interactions with over-the-counter medications, vitamins, or herbal supplements, but clinical discretion advised.
Antibiotic prophylaxis may be required in patients initiating Soliris without up-to-date meningococcal vaccination.
No reported interference with common laboratory test results, but clinical monitoring remains important.
Caution advised when coadministered with other monoclonal antibodies due to additive immunosuppression.
Possible interaction with drugs influencing complement system dynamics, though clinical significance unclear.
No known interactions reported with anticoagulants or antiplatelet agents, yet monitoring is prudent due to thrombotic risk.
Limited data on interactions with novel therapies; consider case-by-case evaluation.
Adjunct therapies for PNH or aHUS (e.g., plasma exchange) may alter pharmacokinetics or pharmacodynamics.
Inform healthcare providers about any new medications started during therapy with Soliris.

Preparations Of The Drug

Soliris is prepared as a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution.
Available as a single-dose vial containing 300 mg of eculizumab in 30 mL (10 mg/mL).
Inactive ingredients include polysorbate 80 (vegetable origin), sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, and Water for Injection.
Stored under refrigerated conditions (2°C to 8°C) and protected from light until administration.
Must be inspected visually for particulate matter and discoloration prior to use.
Preparation requires aseptic technique and dilution according to prescribing information before intravenous infusion.
Diluted solution should be administered promptly; unused portions must be discarded as no preservative is present.
Compatible infusion fluids include 0.9% Sodium Chloride Injection for intravenous administration.
Prepared infusion bags can be stored refrigerated for a limited duration based on manufacturer recommendations.
Packaging designed for single use to avoid contamination and ensure dosing accuracy.
No known incompatibilities with infusion equipment but follow institutional protocols for monoclonal antibody infusions.
Handling precautions include minimizing agitation to preserve antibody integrity.
Preparation preferably conducted by trained healthcare professionals in accordance with REMS program guidelines.
Biosimilar preparations (Bkemv, Epysqli) have similar formulations and storage conditions.
Patient Safety Cards and information materials are provided with drug dispensation to ensure informed administration and safety monitoring.